Evidence map›Paper›PMID 42284682›Full record

ArticleEBioMedicine2026

Predicting accumulation and age at onset of amyloid-β from genetic risk and resilience for Alzheimer's disease.

Eleanor K O'Brien, Timothy Cox, Shane Fernandez, Pierrick Bourgeat, Tenielle Porter, Ben Goudey, James D Doecke, Colin L Masters, Jurgen Fripp, Kwangsik Nho and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EBioMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Eleanor K O'BrienCentre for Precision Health, Edith Cowan University, Joondalup, Western Australia, Australia; Collaborative Genomics and Translation Group, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia. Electronic address: e.obrien@ecu.edu.au.
Timothy CoxAustralian e-Health Research Centre, CSIRO, Parkville, Victoria, Australia.
Shane FernandezCentre for Precision Health, Edith Cowan University, Joondalup, Western Australia, Australia; Collaborative Genomics and Translation Group, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia.
Pierrick BourgeatAustralian e-Health Research Centre, CSIRO, Herston, Queensland, Australia.
Tenielle PorterCentre for Precision Health, Edith Cowan University, Joondalup, Western Australia, Australia; Collaborative Genomics and Translation Group, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia; Curtin Medical School, Curtin University, Bentley, Western Australia, Australia.
Ben GoudeyAustralia BioCommons, The University of Melbourne, North Melbourne, Victoria, Australia; Florey Institute, The University of Melbourne, Parkville, Victoria, Australia.
James D DoeckeCentre for Precision Health, Edith Cowan University, Joondalup, Western Australia, Australia; Australian e-Health Research Centre, CSIRO, Herston, Queensland, Australia.
Colin L MastersFlorey Institute, The University of Melbourne, Parkville, Victoria, Australia.
Jurgen FrippAustralian e-Health Research Centre, CSIRO, Herston, Queensland, Australia.
Kwangsik NhoIndiana Alzheimer's Disease Research Center, Indiana University School of Medicine, Indianapolis, IN, USA.
Victor L VillemagneCentre for Precision Health, Edith Cowan University, Joondalup, Western Australia, Australia; Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA.
Carlos CruchagaDepartment of Psychiatry, Washington University, St. Louis, MO, 63110, USA; NeuroGenomics and Informatics, Washington University, St. Louis, MO, 63110, USA.
Christopher C RoweFlorey Institute, The University of Melbourne, Parkville, Victoria, Australia; Department of Molecular Imaging & Therapy and Centre for PET, Austin Health, Heidelberg, Victoria, Australia.
Andrew J SaykinIndiana Alzheimer's Disease Research Center, Indiana University School of Medicine, Indianapolis, IN, USA; Center for Neuroimaging, Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN, USA.
Vincent DoréAustralian e-Health Research Centre, CSIRO, Parkville, Victoria, Australia; Department of Molecular Imaging & Therapy and Centre for PET, Austin Health, Heidelberg, Victoria, Australia.
Simon M LawsCentre for Precision Health, Edith Cowan University, Joondalup, Western Australia, Australia; Collaborative Genomics and Translation Group, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia; Curtin Medical School, Curtin University, Bentley, Western Australia, Australia. Electronic address: s.laws@ecu.edu.au.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAccumulation of brain amyloid beta (Aβ), a key pathological hallmark of Alzheimer's disease (AD), begins decades before cognitive symptoms. Being able to predict the risk of Aβ accumulation, or the age at which Aβ exceeds a critical threshold, may enable intervention to delay or prevent onset of AD.

methodsUsing published genome-wide association studies (GWASs), we developed polygenic scores (PGS) for AD risk (PGS

findingsHigher genetic risk of AD predicted increased odds of Aβ accumulation (OR = 1.16; 95% CI = 1.05-1.29; p = 0.003) and younger AAO-Aβ (β = -1.32; SE = 0.31; p = 1.63 × 10

interpretationPolygenic scores, alongside other risk factors, may help identify individuals at risk of accumulating Aβ, and predict the age at which this exceeds a critical threshold. This could provide a window for administering disease-modifying treatment or lifestyle interventions to prevent or delay the onset of AD.

fundingNational Institutes of Health (R01-AG058676-01A1) and Australian National Health and Medical Research Council (GNT1161706; GNT2001320).

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesGenetic Predisposition to DiseaseAgedAge of OnsetFemaleGenetic Risk ScoreGenome-Wide Association StudyHumansMaleMultifactorial InheritancePhenotypePolymorphism, Single NucleotideRisk FactorsAmyloid beta-PeptidesAge at onset of amyloid betaAlzheimer's diseaseAmyloid beta accumulationPolygenic scoresResilienceRisk

Identifiers

PMID42284682
PMCPMC13276526

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.